WDR3 promotes stem cell-like properties in prostate cancer by inhibiting USF2-mediated transcription of RASSF1A
- PMID: 36905106
- DOI: 10.1002/jgm.3498
WDR3 promotes stem cell-like properties in prostate cancer by inhibiting USF2-mediated transcription of RASSF1A
Abstract
Background: WD repeat domain 3 (WDR3) is involved in tumor growth and proliferation, but its role in the pathological mechanism of prostate cancer (PCa) is still unclear.
Methods: WDR3 gene expression levels were obtained by analyzing databases and our clinical specimens. The expression levels of genes and proteins were determined by a real-time polymerase chain reaction, western blotting and immunohistochemistry, respectively. Cell-counting kit-8 assays were used to measure the proliferation of PCa cells. Cell transfection was used to investigate the role of WDR3 and USF2 in PCa. Fluorescence reporter and chromatin immunoprecipitation assays were used to detect USF2 binding to the promoter region of RASSF1A. Mouse experiments were used to confirm the mechanism in vivo.
Results: By analyzing the database and our clinical specimens, we found that WDR3 expression was significantly increased in PCa tissues. Overexpression of WDR3 enhanced PCa cell proliferation, decreased cell apoptosis rate, increased spherical cell number and increased indicators of stem cell-like properties. However, these effects were reversed by WDR3 knockdown. WDR3 was negatively correlated with USF2, which was degraded by promoting ubiquitination of USF2, and USF2 interacted with promoter region-binding elements of RASSF1A to depress PCa stemness and growth. In vivo studies showed that WDR3 knockdown reduced tumor size and weight, reduced cell proliferation and enhanced cell apoptosis.
Conclusions: WDR3 ubiquitinated USF2 and inhibited its stability, whereas USF2 interacted with promoter region-binding elements of RASSF1A. USF2 transcriptionally activated RASSF1A, which inhibited the carcinogenic effect of WDR3 overexpression.
Keywords: RASSF1A; USF2; WDR3; cancer stem cell; prostate cancer.
© 2023 John Wiley & Sons Ltd.
Similar articles
-
Tumor-suppression function of transcription factor USF2 in prostate carcinogenesis.Oncogene. 2006 Jan 26;25(4):579-87. doi: 10.1038/sj.onc.1209079. Oncogene. 2006. PMID: 16186802
-
hsa-miR-875-5p inhibits tumorigenesis and suppresses TGF-β signalling by targeting USF2 in gastric cancer.J Transl Med. 2022 Mar 7;20(1):115. doi: 10.1186/s12967-022-03253-6. J Transl Med. 2022. PMID: 35255935 Free PMC article.
-
S100A8 promotes epithelial-mesenchymal transition and metastasis under TGF-β/USF2 axis in colorectal cancer.Cancer Commun (Lond). 2021 Feb;41(2):154-170. doi: 10.1002/cac2.12130. Epub 2021 Jan 3. Cancer Commun (Lond). 2021. PMID: 33389821 Free PMC article.
-
Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer.J Exp Clin Cancer Res. 2021 Mar 1;40(1):88. doi: 10.1186/s13046-021-01879-w. J Exp Clin Cancer Res. 2021. PMID: 33648545 Free PMC article.
-
Upstream stimulatory factor 2 and hypoxia-inducible factor 2α (HIF2α) cooperatively activate HIF2 target genes during hypoxia.Mol Cell Biol. 2012 Nov;32(22):4595-610. doi: 10.1128/MCB.00724-12. Epub 2012 Sep 10. Mol Cell Biol. 2012. PMID: 22966206 Free PMC article.
Cited by
-
Development of nucleus-targeted histone-tail-based photoaffinity probes to profile the epigenetic interactome in native cells.Nat Commun. 2025 Jan 6;16(1):415. doi: 10.1038/s41467-024-55046-8. Nat Commun. 2025. PMID: 39762271 Free PMC article.
-
A novel prognostic model based on pyroptosis signature in AML.Heliyon. 2024 Aug 22;10(17):e36624. doi: 10.1016/j.heliyon.2024.e36624. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39263179 Free PMC article.
-
Transcriptome analysis of the adenoma-carcinoma sequences identifies novel biomarkers associated with development of canine colorectal cancer.Front Vet Sci. 2023 Nov 29;10:1192525. doi: 10.3389/fvets.2023.1192525. eCollection 2023. Front Vet Sci. 2023. PMID: 38098990 Free PMC article.
-
WDR3 undergoes phase separation to mediate the therapeutic mechanism of Nilotinib against osteosarcoma.J Exp Clin Cancer Res. 2025 Jul 11;44(1):201. doi: 10.1186/s13046-025-03456-x. J Exp Clin Cancer Res. 2025. PMID: 40646517 Free PMC article.
References
REFERENCES
-
- Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32(17-18):1105-1140. doi:10.1101/gad.315739.118
-
- Schatten H. Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies. Adv Exp Med Biol. 2018;1095:1-14. doi:10.1007/978-3-319-95693-0_1
-
- Bott SRJ, Ng KL (Eds). Prostate cancer. Brisbane (AU); 2021. doi:10.36255/exonpublications.prostatecancer.2021
-
- Murillo-Garzon V, Kypta R. WNT signalling in prostate cancer. Nat Rev Urol. 2017;14(11):683-696. doi:10.1038/nrurol.2017.144
-
- Sebesta EM, Anderson CB. The surgical management of prostate cancer. Semin Oncol. 2017;44(5):347-357. doi:10.1053/j.seminoncol.2018.01.003
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases